About this episode

The episode discusses the results of the Phase 3 FIGHT-302 trial on Pemigatinib for treating unresectable or metastatic cholangiocarcinoma.

JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper " Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial ." LINK TO FULL TRANSCRIPT

More episodes of Journal of Clinical Oncology (JCO) Podcast

• Effectiveness of a Virtual Tobacco Treatment for Cancer Patients · July 16, 2026 · 24 min
• Phase 2 Study of Multi-Cancer Detection from Breath Samples · June 11, 2026 · 20 min
• JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma · June 1, 2026 · 10 min
• JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS · May 31, 2026 · 11 min
• JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC · May 31, 2026 · 9 min
• JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC · May 29, 2026 · 13 min

Explore listener stats, chart rankings, contacts and more on the Journal of Clinical Oncology (JCO) Podcast podcast page.